Eisai Submits Fycompa Pediatric Indications to FDA
Eisai Inc. submitted a supplemental New Drug Application for priority review to the U.S. FDA for the company’s antiepileptic drug Fycompa (perampanel) CIII as monotherapy and adjunctive use.
New CDC Director Pledges to Take on AIDS and Opioid Epidemics
Days after being tapped to helm the U.S. Centers for Disease Control and Prevention (CDC), Dr. Robert Redfield predicted the AIDS epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”
Researchers Develop Possible New RNA Therapy for West Nile Virus
A research group at Yale University and from Hanyang University, South Korea, developed a new RNA therapy for West Nile Virus.
Sunovion Submits NDA for Sublingual PD Treatment
Sunovion Pharmaceuticals announced the submission of a new drug application to the U.S. FDA for apomorphine sublingual film to treat OFF episodes in Parkinson’s disease (PD).
FDA Approves Amgen’s Blincyto for ALL
The FDA approved Amgen’s supplemental Biologic License Application for Blincyto (blinatumomab) to treat B-cell precursor acute lymphoblastic leukemia (ALL) under specific circumstances.
Coffee sellers in California must have cancer warning
Starbucks Corp. and other coffee sellers must put a cancer warning on coffee sold in California, a Los Angeles judge ruled, possibly exposing the companies to millions of dollars in fines.
Arkansas sues opioid manufacturers
Arkansas’ attorney general joined the widening mass of litigation against opioid manufacturers, accusing three drugmakers of promoting addictive painkillers in ways that falsely denied or trivialized their risks.
Sandbox Opens Contemporary New Workspace in Kansas City
Sandbox announced the opening of the independent, full-service agency’s new office space in Kansas City, Mo., uniting its two local locations under one roof.
Rare heart disease drug succeeds in late-stage study
Pfizer Inc.’s experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.
Unum Captures Nearly $70 Million in IPO
In an initial public offering, Unum Therapeutics snagged nearly $70 million to fund its antibody-coupled T-cell receptor technology.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!